JPWO2020123327A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020123327A5
JPWO2020123327A5 JP2021532224A JP2021532224A JPWO2020123327A5 JP WO2020123327 A5 JPWO2020123327 A5 JP WO2020123327A5 JP 2021532224 A JP2021532224 A JP 2021532224A JP 2021532224 A JP2021532224 A JP 2021532224A JP WO2020123327 A5 JPWO2020123327 A5 JP WO2020123327A5
Authority
JP
Japan
Prior art keywords
seq
piggybac transposase
nucleic acid
piggybac
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532224A
Other languages
Japanese (ja)
Other versions
JP7441840B2 (en
JP2022512332A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065129 external-priority patent/WO2020123327A1/en
Publication of JP2022512332A publication Critical patent/JP2022512332A/en
Publication of JPWO2020123327A5 publication Critical patent/JPWO2020123327A5/ja
Application granted granted Critical
Publication of JP7441840B2 publication Critical patent/JP7441840B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (26)

配列番号2の147位、176位、221位、247位、429位、533位、及び573位の1つ以上でのアミノ酸置換を含む、piggyBacトランスポザーゼ。 A piggyBac transposase comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533 and 573 of SEQ ID NO:2. 配列番号2の147位、176位、221位、及び247位の1つ以上でのイソロイシンのロイシンとのアミノ酸置換を含む、請求項1に記載のpiggyBacトランスポザーゼ。 2. The piggyBac transposase of claim 1, comprising amino acid substitutions of isoleucine with leucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO:2. 配列番号2の429位、533位、及び573位の1つ以上でのセリンのトレオニンとのアミノ酸置換を含む、請求項1に記載のpiggyBacトランスポザーゼ。 2. The piggyBac transposase of claim 1, comprising amino acid substitutions of serine with threonine at one or more of positions 429, 533, and 573 of SEQ ID NO:2. 配列番号2の147位、176位、221位、及び247位の1つ以上でのイソロイシンのロイシンとのアミノ酸置換、並びに/又は配列番号2の429位、533位、及び573位の1つ以上でのセリンのトレオニンとのアミノ酸置換を含む、請求項1に記載のpiggyBacトランスポザーゼ。 Amino acid substitution of isoleucine with leucine at one or more of positions 147, 176, 221 and 247 of SEQ ID NO:2 and/or one or more of positions 429, 533 and 573 of SEQ ID NO:2 2. The piggyBac transposase of claim 1, comprising an amino acid substitution of threonine for serine at . 以下の配列番号2の147位でのイソロイシンのロイシンとのアミノ酸置換、配列番号2の247位でのイソロイシンのロイシンとのアミノ酸置換、及び配列番号2の533位でのセリンのトレオニンとのアミノ酸置換のうちの少なくとも1つを含む、請求項4に記載のpiggyBacトランスポザーゼ。 The following amino acid substitution of isoleucine with leucine at position 147 of SEQ ID NO: 2, amino acid substitution of isoleucine with leucine at position 247 of SEQ ID NO: 2, and amino acid substitution of serine with threonine at position 533 of SEQ ID NO: 2 5. The piggyBac transposase of claim 4, comprising at least one of 以下の配列番号2の147位でのイソロイシンのロイシンとのアミノ酸置換、配列番号2の247位でのイソロイシンのロイシンとのアミノ酸置換、及び配列番号2の533位でのセリンのトレオニンとのアミノ酸置換のうちの少なくとも2つを含む、請求項4に記載のpiggyBacトランスポザーゼ。 The following amino acid substitution of isoleucine with leucine at position 147 of SEQ ID NO: 2, amino acid substitution of isoleucine with leucine at position 247 of SEQ ID NO: 2, and amino acid substitution of serine with threonine at position 533 of SEQ ID NO: 2 5. The piggyBac transposase of claim 4, comprising at least two of: 配列番号2の147位でのイソロイシンのロイシンとの置換、配列番号2の247位でのイソロイシンのロイシンとの置換、及び配列番号2の533位でのセリンのトレオニンとの置換を含む、請求項4に記載のpiggyBacトランスポザーゼ。 2. Substitution of leucine for isoleucine at position 147 of SEQ ID NO:2, substitution of leucine for isoleucine at position 247 of SEQ ID NO:2, and substitution of threonine for serine at position 533 of SEQ ID NO:2. 4. The piggyBac transposase according to 4. 改変されたpiggyBacトランスポザーゼでトランスフェクトされた細胞によって発現される目的の組換えタンパク質の力価が、野生型piggyBacトランスポザーゼで、又はpiggyBacトランスポザーゼなしでトランスフェクトされた細胞によって発現される同じ目的のタンパク質の力価と比較して改善される、請求項1に記載のpiggyBacトランスポザーゼ。 The titer of the recombinant protein of interest expressed by cells transfected with the modified piggyBac transposase is higher than the titer of the same protein of interest expressed by cells transfected with wild-type piggyBac transposase or without piggyBac transposase. 2. The piggyBac transposase of claim 1, which is improved relative to potency. 前記目的の組換えタンパク質が、抗原結合タンパク質である、請求項8に記載のpiggyBacトランスポザーゼ。 9. The piggyBac transposase of claim 8, wherein said recombinant protein of interest is an antigen binding protein. 配列番号4、配列番号6、配列番号8、配列番号10、配列番号12、配列番号14、又は配列番号16のアミノ酸配列を有するpiggyBacトランスポザーゼ。 A piggyBac transposase having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16. 請求項1又は10に記載のpiggyBacトランスポザーゼをコードする改変された核酸分子。 11. A modified nucleic acid molecule encoding the piggyBac transposase of claim 1 or 10. 配列番号3、配列番号5、配列番号7、配列番号9、配列番号11、配列番号13、配列番号15、配列番号17、又は配列番号18の核酸配列によりコードされるpiggyBacトランスポザーゼ。 A piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18. 請求項11又は12に記載のpiggyBacトランスポザーゼをコードする前記核酸分子を含むベクター。 13. A vector comprising said nucleic acid molecule encoding the piggyBac transposase of claim 11 or 12. 請求項11又は12に記載のpiggyBacトランスポザーゼをコードする前記核酸分子を含むベクターであって、piggyBacトランスポゾンの少なくとも5’及び3’の逆位反復エレメントに隣接する少なくとも1つの目的のタンパク質をコードする少なくとも1つの核酸配列を更に含む、ベクター。 13. A vector comprising said nucleic acid molecule encoding the piggyBac transposase of claim 11 or 12, said vector encoding at least one protein of interest flanking at least the 5' and 3' inverted repeat elements of the piggyBac transposon. A vector further comprising a nucleic acid sequence. 請求項12に記載の核酸配列によってコードされるpiggyBacトランスポザーゼでトランスフェクトされた細胞。 A cell transfected with a piggyBac transposase encoded by the nucleic acid sequence of claim 12. 請求項13に記載のベクターでトランスフェクトされた細胞。 A cell transfected with the vector of claim 13. 前記細胞が、宿主細胞である、請求項15又は16に記載の細胞。 17. The cell of claim 15 or 16, wherein said cell is a host cell. 前記細胞が、CHO細胞である、請求項15又は16に記載の細胞。 17. The cell according to claim 15 or 16, wherein said cell is a CHO cell. 前記細胞が、免疫細胞である、請求項15又は16に記載の細胞。 17. The cell of claim 15 or 16, wherein said cell is an immune cell. 請求項11に記載のpiggyBacトランスポザーゼをコードする改変された核酸分子、並びにpiggyBacトランスポゾンの少なくとも5’及び3’の逆位反復エレメントに隣接する少なくとも1つの目的のタンパク質をコードする少なくとも1つの核酸分子を含むベクターでコトランスフェクトされた細胞。 a modified nucleic acid molecule encoding the piggyBac transposase of claim 11 and at least one nucleic acid molecule encoding at least one protein of interest flanking at least the 5′ and 3′ inverted repeat elements of the piggyBac transposon; Cells co-transfected with the containing vector. 請求項13に記載のpiggyBacトランスポザーゼをコードする改変された核酸分子を含むベクター、並びにpiggyBacトランスポゾンの少なくとも5’及び3’の逆位反復エレメントに隣接する少なくとも1つの目的のタンパク質をコードする少なくとも1つの核酸分子を含むベクターでコトランスフェクトされた細胞。 14. A vector comprising a modified nucleic acid molecule encoding the piggyBac transposase of claim 13 and at least one protein encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. A cell co-transfected with a vector containing a nucleic acid molecule. 請求項13に記載のpiggyBacトランスポザーゼをコードする改変された核酸分子を含み、並びにpiggyBacトランスポゾンの少なくとも5’及び3’の逆位反復エレメントに隣接する少なくとも1つの目的のタンパク質をコードする少なくとも1つの核酸分子を含むベクターでコトランスフェクトされた細胞。 14. At least one nucleic acid comprising a modified nucleic acid molecule encoding the piggyBac transposase of claim 13 and encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon Cells co-transfected with a vector containing the molecule. 改変されたpiggyBacトランスポザーゼでトランスフェクトされた前記細胞によって発現される目的のタンパク質の力価が、野生型piggyBacトランスポザーゼで、又はpiggyBacトランスポザーゼなしでトランスフェクトされた細胞によって発現される同じ目的のタンパク質の力価と比較して改善される、請求項15、16、20、21又は22のいずれか一項に記載の細胞。 The titer of the protein of interest expressed by said cells transfected with the modified piggyBac transposase is the same titer of the protein of interest expressed by cells transfected with wild-type piggyBac transposase or without piggyBac transposase. 23. The cell of any one of claims 15, 16, 20, 21 or 22, wherein the cell is improved as compared to titer. 宿主細胞によって発現される目的の組換えタンパク質の力価を改善するための方法であって、
前記宿主細胞の安定性を高めるようにpiggyBacトランスポザーゼをコードする核酸分子を改変することと;
前記piggyBacトランスポザーゼをコードする改変された核酸分子、並びにpiggyBacトランスポゾンの少なくとも5’及び3’の逆位反復エレメントに隣接する前記目的のタンパク質をコードする核酸配列を含むベクターで前記宿主細胞をコトランスフェクトすることと;
前記細胞を培養して前記目的の組換えタンパク質を発現させることと
を含み、
改変されたpiggyBacトランスポザーゼでトランスフェクトされた前記宿主細胞によって発現される前記目的の組換えタンパク質の力価が、野生型piggyBacトランスポザーゼで、又はpiggyBacトランスポザーゼなしでトランスフェクトされた宿主細胞によって発現される前記目的の組換えタンパク質の力価と比較して改善される、方法。
A method for improving the titer of a recombinant protein of interest expressed by a host cell comprising:
modifying a nucleic acid molecule encoding a piggyBac transposase to increase stability of said host cell;
co-transfecting said host cell with a vector comprising a modified nucleic acid molecule encoding said piggyBac transposase and a nucleic acid sequence encoding said protein of interest flanked by at least the 5′ and 3′ inverted repeat elements of the piggyBac transposon; to do;
culturing said cells to express said recombinant protein of interest;
the titer of said recombinant protein of interest expressed by said host cells transfected with the modified piggyBac transposase expressed by host cells transfected with wild-type piggyBac transposase or without piggyBac transposase; A method wherein the potency of the recombinant protein of interest is improved compared to.
前記宿主細胞が、前記piggyBacトランスポザーゼをコードする前記改変された核酸分子を含む第1のベクター、並びにpiggyBacトランスポゾンの少なくとも5’及び3’の逆位反復エレメントに隣接する前記目的のタンパク質をコードする核酸配列を含む第2のベクターでトランスフェクトされる、請求項24に記載の方法。 said host cell comprises a first vector comprising said modified nucleic acid molecule encoding said piggyBac transposase and nucleic acid encoding said protein of interest flanked by at least the 5′ and 3′ inverted repeat elements of the piggyBac transposon; 25. The method of claim 24, transfected with a second vector containing the sequence. 前記宿主細胞が、前記piggyBacトランスポザーゼをコードする前記改変された核酸分子、並びにpiggyBacトランスポゾンの少なくとも5’及び3’の逆位反復エレメントに隣接する前記目的のタンパク質をコードする核酸配列を含む単一のベクターでトランスフェクトされる、請求項24に記載の方法。 said host cell comprising said modified nucleic acid molecule encoding said piggyBac transposase and a nucleic acid sequence encoding said protein of interest flanked by at least the 5′ and 3′ inverted repeat elements of the piggyBac transposon; 25. The method of claim 24, wherein the vector is transfected.
JP2021532224A 2018-12-10 2019-12-09 Mutated PIGGYBAC transposase Active JP7441840B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862777325P 2018-12-10 2018-12-10
US62/777,325 2018-12-10
US201962925516P 2019-10-24 2019-10-24
US62/925,516 2019-10-24
PCT/US2019/065129 WO2020123327A1 (en) 2018-12-10 2019-12-09 Mutated piggybac transposase

Publications (3)

Publication Number Publication Date
JP2022512332A JP2022512332A (en) 2022-02-03
JPWO2020123327A5 true JPWO2020123327A5 (en) 2022-11-01
JP7441840B2 JP7441840B2 (en) 2024-03-01

Family

ID=69143664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532224A Active JP7441840B2 (en) 2018-12-10 2019-12-09 Mutated PIGGYBAC transposase

Country Status (14)

Country Link
US (1) US20220064610A1 (en)
EP (1) EP3894549A1 (en)
JP (1) JP7441840B2 (en)
KR (1) KR20210101270A (en)
CN (1) CN113195712A (en)
AU (1) AU2019398101A1 (en)
BR (1) BR112021011063A2 (en)
CA (1) CA3121268A1 (en)
CL (1) CL2021001488A1 (en)
IL (1) IL283314A (en)
MX (1) MX2021006783A (en)
SG (1) SG11202106049RA (en)
TW (1) TW202035687A (en)
WO (1) WO2020123327A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122716A1 (en) * 2021-12-22 2023-06-29 Vanderbilt University Next generation transpososomes
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP0873405B1 (en) 1996-01-11 2004-09-08 Immunex Corporation Expression augmenting sequence elements (ease) for eukaryotic expression systems
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (en) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 Simultaneous stimulation and concentration of cells
US7932088B1 (en) * 2005-04-25 2011-04-26 University Of Notre Dame Du Lac High efficiency transformation of Plasmodium falciparum by the lepidopteran transposon, piggyBac
US20110311506A1 (en) 2009-02-25 2011-12-22 The Johns Hopkins University Piggybac transposon variants and methods of use
US8399643B2 (en) 2009-02-26 2013-03-19 Transposagen Biopharmaceuticals, Inc. Nucleic acids encoding hyperactive PiggyBac transposases
US20100311116A1 (en) 2009-06-04 2010-12-09 Excellgene Sa Fast generation of high expression stable cell lines expressing recombinant proteins under minimal and short-term selective pressure
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
GB201014169D0 (en) 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
PT3214091T (en) 2010-12-09 2019-01-11 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112013024395B1 (en) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center ADOPTIVE COMPOSITIONS OF CELL IMMUNOTHERAPY AND METHOD FOR MANUFACTURING SUCH COMPOSITION
WO2013012824A2 (en) 2011-07-15 2013-01-24 The Johns Hopkins University Trichoplusia ni piggybac transposases with reduced integration activity
CN103360464A (en) * 2013-07-17 2013-10-23 武汉摩尔生物科技有限公司 Polypeptide, DNA molecule encoding polypeptide, vector, preparation method and application thereof
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
DK3129487T3 (en) * 2014-04-09 2020-11-30 Dna Twopointo Inc IMPROVED NUCLEIC ACID CONSTRUCTIONS FOR EUKARYOT GENEPRESSION
EP3018200A1 (en) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
WO2018098671A1 (en) 2016-11-30 2018-06-07 China Agricultural University A method for crispr library screening

Similar Documents

Publication Publication Date Title
JP2014239686A5 (en)
US20220347289A1 (en) Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
JP2017513479A5 (en)
JP2012095652A5 (en)
JP2005120106A5 (en)
RU2013152648A (en) Adenovirus Monkeys And Hybrid Adenovirus Vectors
EA020969B1 (en) Optimisation of expression of parvoviral rep and cap proteins in insect cells
WO2013065772A1 (en) Method for secreting and producing proteins
WO2018030499A1 (en) Production method for insoluble recombinant protein aggregate
JP2009529868A5 (en)
RU2009148322A (en) NEW LYSOPHOSPHATID ACID ACYLTRANESPHERASES GENES
Estes et al. Uncovering methods for the prevention of protein aggregation and improvement of product quality in a transient expression system
JP2005509420A5 (en)
JPWO2020123327A5 (en)
PE20221254A1 (en) ISOLATED MODIFIED VP1 PROTEIN FROM THE CAPSIDE OF THE ADENO-ASSOCIATED VIRUS SEROTYPE 5 (AAV5), CAPSIDE AND VECTOR BASED ON THE SAME
JP2015518728A (en) Production cell line enhancer
RU2020116307A (en) MODIFIED NOROVIRUS VP1 PROTEINS AND VLP CONTAINING MODIFIED NOROVIRUS VP1 PROTEINS
Bae et al. Hyper-enhanced production of foreign recombinant protein by fusion with the partial polyhedrin of nucleopolyhedrovirus
JP2013502217A5 (en)
Chen et al. Small P particles formed by the Taiwan-native norovirus P domain overexpressed in Komagataella pastoris
Zhang et al. Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform
US20150037866A1 (en) Composition, Method and Kit for Obtaining Purified Recombinant Proteins
RU2546242C1 (en) RECOMBINANT STRAIN OF YEAST Hansenula polymorpha - PRODUCER OF MAJOR CAPSID PROTEIN L1 OF HUMAN PAPILLOMAVIRUS OF TYPE 18
WO2010079982A3 (en) Consistent high expression vector containing rep e mutated gene
WO2018212467A1 (en) Fusion protein having c-terminal sequence of lamprey-derived vlrb protein connected to hagfish-derived vlrb protein having hydrophobic tail domain removed therefrom, and use thereof